Ascendis Pharma A/S Newsroom

Ascendis Pharma Is Maintained at Buy by TD Cowen

Dow Jones01:25 · Ratings

TD Cowen Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $160

Futu NewsOct 21 19:31 · Ratings

Ascendis Pharma Ticks Higher Amid Report It Cancelled From Upcoming Conference

Seeking AlphaOct 17 00:11

MBX Bio Drops Despite Bullish Views on Street

Seeking AlphaOct 9 03:15

Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167

Futu NewsOct 7 21:34 · Ratings

Septerna, Hypoparathyroidism Drug Developer, Files for $100M IPO

Seeking AlphaOct 4 01:36

Ascendis Pharma Submits Supplemental Biologics License Application for Pediatric Growth Hormone Drug

MT NewswiresSep 30 21:23

Ascendis Pharma Presents 3-Year Data At ASBMR 2024 Showing Long-Term Treatment With TransCon PTH Normalizes Bone Remodeling In Adults With Hypoparathyroidism

BenzingaSep 30 20:33

Looking Into Ascendis Pharma's Recent Short Interest

BenzingaSep 26 23:00

European Equities Traded in the US as American Depositary Receipts Trend Lower Wednesday

MT NewswiresSep 25 23:07

Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years

BenzingaSep 25 05:30

Ascendis Pharma A/S | 6-K: Report of foreign private issuer (related to financial reporting)

SECSep 24 04:04 · Announcements

B of A Securities Maintains Buy on Ascendis Pharma, Raises Price Target to $191

BenzingaSep 24 00:04 · Ratings

Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167

Morgan Stanley analyst Vikram Purohit maintains $Ascendis Pharma A/S(ASND.US)$ with a hold rating, and maintains the target price at $167.According to TipRanks data, the analyst has a success rate

Futu NewsSep 23 21:32 · Ratings

BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $191

BofA Securities analyst Tazeen Ahmad maintains $Ascendis Pharma A/S(ASND.US)$ with a buy rating, and adjusts the target price from $175 to $191.According to TipRanks data, the analyst has a success

Futu NewsSep 23 20:33 · Ratings

Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?

BenzingaSep 23 05:04

Sector Update: Health Care Stocks Rise Premarket Friday

MT NewswiresSep 20 21:28

Ascendis: Granted Underwriters 30-Day Option to Purchase Up to an Additional 300,000 ADSs>ASND

Dow JonesSep 20 09:58

All of the ADSs Are Being Offered by Ascendis >ASND

Dow JonesSep 20 09:58

European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading

MT NewswiresSep 19 23:06